iRhythm Holdings, Inc.
Moat Score — iRhythm Holdings, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | iRhythm's FDA-cleared deep-learning ECG algorithms (ZEUS) were trained on one of the largest ambulatory ECG datasets in the industry, built over more than a decade of Zio patch deployments, giving it a data and clinical-evidence advantage (backed by the CAMELOT and AVALON studies) that a new entrant cannot replicate quickly even with comparable hardware. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Owning its manufacturing facility in Cypress, California and its own Medicare-enrolled diagnostic testing facilities gives iRhythm some vertical-integration efficiency versus smaller rivals, but its 2025 net loss of $44.6 million shows it does not yet have a decisive cost advantage over deep-pocketed rivals like Philips-owned BioTelemetry or Boston Scientific-owned Preventice. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | iRhythm's claimed 40%+ penetration of the core ACM market and 70%+ share of LTCM services give it real leverage in payor negotiations, reflected in gross margin improving to 70.6% in 2025, though CPT-code-based reimbursement ultimately caps how much pricing power the company can exercise versus Medicare and commercial payors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is a mild data-network effect: every additional Zio recording improves the training data behind iRhythm's ZEUS algorithms, which in turn can improve diagnostic accuracy for future patients, but this is an indirect, slow-moving effect rather than a direct network effect between users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once a health system integrates ZioSuite and myZio into its EHR workflows and physicians become accustomed to iRhythm's reporting format and diagnostic yield, switching to a competing monitoring service means re-training staff and re-validating a new vendor's clinical workflow -- a real, though not insurmountable, source of stickiness. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The ambulatory cardiac monitoring market is large enough that well-capitalized rivals (BioTelemetry/Philips, Preventice/Boston Scientific, BardyDx/Baxter) continue to compete directly, and consumer wearable makers (Apple, Fitbit) are also encroaching from the low end, so the market is not so narrow that it structurally protects iRhythm from well-funded competition. |